Myriad Genetics Stock
Myriad Genetics Stock
We can see a decrease in the price for Myriad Genetics. Compared to yesterday it has lost -€0.200 (-1.090%).
Currently there is a rather positive sentiment for Myriad Genetics with 5 Buy predictions and 2 Sell predictions.
As a result the target price of 23 € shows a positive potential of 27.07% compared to the current price of 18.1 € for Myriad Genetics.
Pros and Cons of Myriad Genetics in the next few years
Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Myriad Genetics vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Myriad Genetics | -1.090% | 9.697% | 0.000% | -5.729% | 2.260% | -27.600% | -38.944% |
Integer Hldg | -2.880% | 0.000% | -5.607% | 38.356% | 13.483% | 30.323% | 59.130% |
Healthequity Inc. | - | 0.000% | -2.649% | 57.051% | 23.529% | 17.150% | - |
Omnicell Inc. | - | -1.563% | 0.000% | -52.453% | -28.000% | -78.824% | -65.299% |
Comments
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $23.00 price target on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $28.00 price target on the stock.
Show more
Ratings data for MYGN provided by MarketBeat